Differences in biomarker testing in non-small cell lung cancer: real-world outcomes within an integrated healthcare system
Clicks: 3
ID: 310289
2025
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.6
/100
3 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #300 of 490 articles by views in Frontiers in surgery
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 490 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
IntroductionWhile biomarker testing can guide lung cancer treatment, its real-world application in community practice remains underexplored. This study examines the prevalence, predictors, and outcomes of biomarker testing in non-small cell lung cancer (NSCLC).MethodsThis retrospective cohort study included adults diagnosed with primary NSCLC from 2013 to 2020 within a large integrated healthcare system. We linked cancer registry and electronic health records to determine the prevalence of biomarker testing, including single-gene, multi-gene, and next-generation sequencing (NGS), overall and stratified by patient characteristics including age, gender, race/ethnicity, smoking status, and stage. Multivariable regression analyses were conducted to identify independent predictors of biomarker testing and evaluate associations between type of biomarker testing and 3-year all-cause mortality, overall and stratified by stage.ResultsAmong 8,267 NSCLC patients, 38.9% received biomarker testing. Testing prevalence increased with disease stage: I (6.9%), II (18.0%), III (34.8%), IV (71.1%). Testing was more prevalent in patients aged <65 years, of Asian race, and who never smoked, lived in less deprived neighborhoods, and had non-squamous tumors. Younger age, never smoking, Asian race, and stage IV disease were independent predictors of biomarker testing. NGS vs. no testing was associated with 13% decreases in 3-year all-cause mortality.ConclusionsBiomarker testing prevalence was higher in advanced stage NSCLC as expected, with decreased 3-year mortality in patients who received NGS testing. Our findings in a large real-world diverse population suggest that broader uptake of comprehensive biomarker testing across all stages of NSCLC is warranted for improved outcomes.
| Reference Key |
imported_1768925838_696faa8e4eff7
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Velotta, Jeffrey B. |
| Journal | Frontiers in surgery |
| Year | 2025 |
| DOI |
10.3389/fsurg.2025.1632360
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.